IQVIA (NYSE:IQV) Insider James Berkshire Sells 2,668 Shares of Stock

Key Points

• IQVIA insider James Berkshire sold 2,668 shares at an average price of $261.33, generating approximately $697,228. After the transaction, he retained 10,890 shares, a 19.68% reduction in his holdings.
• IQVIA reported quarterly adjusted earnings of $3.15 per share and revenue of $4.37 billion, exceeding analyst estimates; revenue rose 8.7% year over year. The company issued fiscal 2026 EPS guidance of $12.80–$13.00.
• The company authorized a $2 billion share-repurchase program, while analysts maintained a generally positive outlook with a consensus “Moderate Buy” rating and several raised price targets.

IQVIA Holdings Inc. (NYSE:IQV - Get Free Report) insider James Berkshire sold 2,668 shares of the business's stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $261.33, for a total transaction of $697,228.44. Following the completion of the transaction, the insider owned 10,890 shares of the company's stock, valued at approximately $2,845,883.70. The trade was a 19.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

IQVIA Stock Down 1.6%

Shares of IQV stock traded down $4.28 during mid-day trading on Friday, hitting $267.34. The company's stock had a trading volume of 1,197,834 shares, compared to its average volume of 1,736,455. The stock has a market cap of $44.00 billion, a price-to-earnings ratio of 33.17, a PEG ratio of 2.25 and a beta of 1.18. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71. IQVIA Holdings Inc. has a 52-week low of $154.50 and a 52-week high of $271.80. The business has a 50-day moving average price of $229.01 and a 200 day moving average price of $192.13.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating analysts' consensus estimates of $3.03 by $0.12. The company had revenue of $4.37 billion for the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The firm's revenue for the quarter was up 8.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Research analysts predict that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA declared that its Board of Directors has approved a share buyback program on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company's board believes its shares are undervalued.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. International Assets Investment Management LLC bought a new position in IQVIA during the fourth quarter valued at approximately $27,000. Compass Financial Management LLC bought a new stake in IQVIA in the 2nd quarter worth approximately $27,000. Gilpin Wealth Management LLC purchased a new stake in shares of IQVIA during the 4th quarter worth approximately $27,000. CrossGen Wealth LLC bought a new position in shares of IQVIA during the 4th quarter valued at approximately $28,000. Finally, Financial Freedom LLC purchased a new position in shares of IQVIA in the first quarter valued at $25,000. Hedge funds and other institutional investors own 89.62% of the company's stock.

Analysts Set New Price Targets

IQV has been the subject of a number of analyst reports. Weiss Ratings upgraded IQVIA from a "hold (c-)" rating to a "hold (c)" rating in a research report on Wednesday, July 15th. TD Cowen boosted their price objective on IQVIA from $233.00 to $288.00 and gave the company a "buy" rating in a research note on Wednesday, July 29th. William Blair upgraded shares of IQVIA to a "strong-buy" rating in a research note on Tuesday, July 28th. Robert W. Baird upped their price target on shares of IQVIA from $252.00 to $287.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 29th. Finally, Stifel Nicolaus increased their price objective on shares of IQVIA from $220.00 to $276.00 and gave the stock a "buy" rating in a research note on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $243.62.

About IQVIA

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source